Cargando…

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS

OBJECTIVE: Comorbidities influence disease assessment in axial spondyloarthritis (axSpA), but their association with response to TNF inhibitors (TNFi) is unclear. We examined associations between comorbidity history at TNFi initiation and: (i) change in disease indices over time; (ii) binary respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Sizheng Steven, Jones, Gareth T, Macfarlane, Gary J, Hughes, David M, Moots, Robert J, Goodson, Nicola J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409999/ https://www.ncbi.nlm.nih.gov/pubmed/33369676 http://dx.doi.org/10.1093/rheumatology/keaa900

Ejemplares similares

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS
por: Macfarlane, Gary J, et al.
Publicado: (2020)

Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis
por: Shim, Joanna, et al.
Publicado: (2018)

Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis
por: Zhao, Sizheng, et al.
Publicado: (2016)

Alcohol and disease activity in axial spondyloarthritis: a cross-sectional study
por: Zhao, Sizheng, et al.
Publicado: (2018)

The prevalence of fibromyalgia in axial spondyloarthritis
por: Jones, Gareth T., et al.
Publicado: (2020)

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis
por: Shim, Joanna, et al.
Publicado: (2020)

The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis
por: Provan, Sella A, et al.
Publicado: (2021)

Comorbid pain in axial spondyloarthritis, including fibromyalgia
por: López-Medina, Clementina, et al.
Publicado: (2020)

Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data
por: Neilson, Aileen R., et al.
Publicado: (2022)

Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study
por: Hauser, Barbara, et al.
Publicado: (2017)

Editorial: Clinical manifestations and comorbidities in axial and peripheral spondyloarthritis
por: Schiotis, Ruxandra Elena, et al.
Publicado: (2022)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
por: Gratacós, Jordi, et al.
Publicado: (2019)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
por: Manica, Santiago Rodrigues, et al.
Publicado: (2020)

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry
por: Michelena, Xabier, et al.
Publicado: (2021)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
por: Vallier, Marie, et al.
Publicado: (2023)

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
por: Zhao, Sizheng Steven, et al.
Publicado: (2023)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
por: Hawley, Samuel, et al.
Publicado: (2019)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
por: Van Rossen, Liz, et al.
Publicado: (2020)

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)
por: Macfarlane, Gary J., et al.
Publicado: (2019)

The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment
por: Macfarlane, Gary J., et al.
Publicado: (2015)

Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA
por: Hamann, Philip D H, et al.
Publicado: (2020)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register
por: Macfarlane, Gary J, et al.
Publicado: (2018)

Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study
por: Hokkanen, Anna-Mari, et al.
Publicado: (2023)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Comorbidities in Spondyloarthritis
por: Moltó, Anna, et al.
Publicado: (2018)

Cytokine profiles in axial spondyloarthritis
por: Madej, Marta, et al.
Publicado: (2015)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Axial Spondyloarthritis and Cigarette Smoking
por: Kaut, Irène Kona, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a7usrktfulaivkl1tura2gb41e